ADMA Biologics Inc will present a poster that describes the efficacy of RI-002, a polyclonal IVIG product, in animal modes of the human Respiratory Syncytial Virus infection.

According to the poster — which will be presented at the 9th International Respiratory Syncytial Virus (RSV) Symposium in Cape Town, South Africa — RI-002 administration reduced viral load. Furthermore, prevented RSV infections in the lungs of immune suppressed cotton rats by also impairing viral dissemination to peripheral organs.